Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

Impact · against what's priced in

Definium Therapeutics (DFTX) has significantly derisked its lead candidate DT120 by meeting all primary and secondary endpoints in its Phase 3 Emerge study with high statistical significance. The positive efficacy and clean safety profile provide a concrete path toward FDA approval for treating major depressive disorder.

DFTX+0.90: No priced-in read yet

Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

What matters in this story

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

What matters in this story

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

How each ticker is affected

Track these names every morning.

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns

Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

What matters in this story

Next reads from the same story arc

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

What matters in this story

Next reads from the same story arc

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

How each ticker is affected

Track these names every morning.

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns